Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Gliosarcoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

Temozolomide 128Radiotherapy 85Bevacizumab 43Radiation 30Carmustine 29Irinotecan 25Erlotinib Hydrochloride 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 20Surgical Procedures, Operative 15O(6)-benzylguanine 15Carboplatin 14sargramostim 12Radiotherapy, Intensity-Modulated 12Radiotherapy, Conformal 12Sirolimus 10Imatinib Mesylate 9Filgrastim 9Drug Therapy 9temsirolimus 8pembrolizumab 8Thalidomide 8Sorafenib 8Radiosurgery 8Gefitinib 8motexafin gadolinium 7aldesleukin 7Procarbazine 7Gene Expression Profiling 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × Receptor Protein-Tyrosine Kinases × Sarcoma × Clear all
NCT01753713 2017-12-12

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Case Comprehensive Cancer Center

Phase 2 Completed
33 enrolled 14 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡